Brainsway Receives FDA Approval
JERUSALEM, Jan. 10, 2013 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) ("Brainsway" or the "Company") is proud to announce that the U.S. Food and Drug Administration ("FDA") has approved its proprietary Deep TMS device for the treatment of depression in patients who have failed to respond to antidepressant medications in their current episode of depression. It should be noted that this indication for the use of Brainsway's device, as approved by the FDA, is broad, both in general terms as it relates to depression therapy and compared to the FDA-approved indications for the use of competing TMS therapy.
The scope of the FDA-approved indication for the use of the Brainsway device provides further confirmation of the safety and efficacy of the Deep TMS technology, developed by Prof. Abraham Zangen at the U.S. National Institutes of Health, in the treatment of depression patients and could fundamentally alter the way in which depression is treated worldwide. Furthermore, this approval represents a major breakthrough for the Company, inasmuch as it grants it access to the U.S. market for depression therapy, which is valued at tens of billions of dollars per year.
Brainsway is currently exploring various avenues for the marketing and distribution of treatments using its Deep TMS device in the U.S. and across the globe, including collaborations with well-known and experienced companies in the industry.Uzi Sofer, CEO of Brainsway, took this occasion to say, "'Give thanks to the LORD, for he is good. For his mercy endures forever' (Psalms 136:1). We have worked tirelessly for almost ten years to make it to this blessed day. These are glad tidings not only for Brainsway, but also for depression patients and their doctors. The broad scope of the FDA's clearance proves conclusively that our device is both safe and effective. I believe this approval will boost awareness and acceptance of Brainsway's Deep TMS technology not only in the U.S., but the world over, as we continue to also work towards achieving regulatory approval from healthcare authorities in Canada and other countries. This is a very happy day for me personally and for every one of the Company's employees who have all contributed to our achievements. I am hopeful that we will have the wisdom to steer Brainsway onto ever-greater achievements moving forward. CNS is a difficult and challenging field and few companies have any projects in their pipelines in this field. We have dozens of products ready to be released, and we hope to obtain clearance for these in the future."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts